We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Multi-Faceted Biomarker Demonstrates Diagnostic Potential for Various Cancers

By LabMedica International staff writers
Posted on 18 Aug 2025

Cancer remains one of the leading causes of mortality worldwide despite significant advancements in medicine. More...

Early detection and reliable prognostic tools are critical to improving survival, yet effective biomarkers applicable across multiple cancer types remain limited. Now, a new study has demonstrated the potential of a single gene to serve as a diagnostic, prognostic, and immunotherapeutic biomarker, offering hope for more precise cancer management.

Researchers from Louisiana State University Health Sciences Center (New Orleans, LA, USA), Tulane University (New Orleans, LA, USA), and collaborators conducted a comprehensive bioinformatics analysis to assess the role of the CISD1 gene in cancer. Using data from multiple public databases, including TCGA, GTEx, THPA, GEPIA2.0, and cBioPortal, they evaluated CISD1’s expression, genetic alterations, and clinical correlations across 33 cancer types. This systematic approach allowed for a broad exploration of its functions in tumor biology.

The results, published in Genes & Diseases, revealed significant changes in CISD1 expression at both transcriptional and translational levels. Mutations, particularly within the zf-CDGSH domain at hotspot site A69S/V, were associated with cancer initiation and progression. High CISD1 expression was linked to poor clinical outcomes, reduced survival, and increased mortality risk. Furthermore, CISD1 correlated with tumor mutation burden, microsatellite instability, and stemness indices, underscoring its prognostic potential.

The study also highlighted CISD1’s link to immunotherapy outcomes. Tumors with high CISD1 expression showed elevated immune checkpoint proteins, making them more likely to respond to immune checkpoint blockade therapies. This establishes CISD1 not only as a diagnostic and prognostic biomarker but also as a predictor of immunotherapeutic effectiveness. Interestingly, CISD1 displayed dual roles, acting as an oncogene in most cancers but showing tumor-suppressive functions in six cancer types.

Looking ahead, targeting CISD1 directly may present new therapeutic opportunities. Strategies such as modulating its protein expression or interfering with its iron-sulfur cluster could improve treatment outcomes. While the study acknowledges limitations, including a lack of experimental validation and heterogeneity across datasets, it lays a strong foundation for deeper exploration of CISD1 in cancer biology and clinical applications. In conclusion, this systematic pan-cancer analysis shows that CISD1 could serve as a reliable and promising diagnostic, prognostic, and immunotherapeutic biomarker in multiple cancers.


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.